The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis.
PD-L1
TIME (tumor immune microenvironment)
immunophenotype
mRCC (metastatic renal cell carcinoma)
metachronous
synchronous
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
received:
28
09
2022
revised:
21
10
2022
accepted:
24
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.
Identifiants
pubmed: 36358675
pii: cancers14215258
doi: 10.3390/cancers14215258
pmc: PMC9656369
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chugai Pharmaceuticals Co. Ltd.
ID : NA
Références
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
ESMO Open. 2021 Jun;6(3):100101
pubmed: 33901870
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Cancers (Basel). 2022 Sep 27;14(19):
pubmed: 36230613
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Clin Genitourin Cancer. 2017 Feb;15(1):e1-e7
pubmed: 27444986
Br J Cancer. 2017 Aug 8;117(4):451-460
pubmed: 28704840
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Clin Cancer Res. 2021 Jan 1;27(1):78-86
pubmed: 32873572
Urol Int. 2020;104(7-8):533-541
pubmed: 32623437
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35304405
Nat Rev Nephrol. 2020 Dec;16(12):721-735
pubmed: 32733094
JAMA Oncol. 2022 Feb 01;8(2):275-280
pubmed: 34940781
Sci Rep. 2020 Apr 10;10(1):6220
pubmed: 32277125
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
World J Urol. 2016 Aug;34(8):1081-6
pubmed: 26847337
Clin Genitourin Cancer. 2017 Dec;15(6):717-723
pubmed: 28552571
JCO Oncol Pract. 2022 Mar;18(3):187-196
pubmed: 34529499
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Vaccines (Basel). 2021 Aug 18;9(8):
pubmed: 34452045
Eur Urol Oncol. 2020 Aug;3(4):530-539
pubmed: 32037304
Cancer. 2017 Dec 15;123(24):4823-4831
pubmed: 28832979
Eur Urol. 2020 Apr;77(4):449-453
pubmed: 31732098
Cancers (Basel). 2022 Aug 01;14(15):
pubmed: 35954418
Int J Clin Oncol. 2021 Nov;26(11):2073-2084
pubmed: 34291367